Company intelligence / Profile preview

Lilac Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Lilac Therapeutics develops LLX‑424, a small molecule inhibitor of glycolate oxidase designed to reduce urinary oxalate and prevent recurrent calcium oxalate kidney stones. The company addresses an unmet need as there are currently no approved therapies for most patients to prevent future kidney stones. No published clinical results yet.

Therapeutic areas: Nephrology
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

LLX-424

Beyond the preview

Go deeper on Lilac Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lilac Therapeutics.

Explore the full profile